Humacyte is trading up 5% at $0.66. The stock is receiving a boost after BTIG Research issued a Buy Rating today, July 30. This also reflects continued investor interest following the recent FDA Investigational New Drug (IND) clearance announced on July 27, 2026. The upward movement is supported by a broadly positive market backdrop.